Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan-Feb;16(1):71-79.
doi: 10.21873/cgp.20113.

MiR-1 Suppresses Proliferation of Osteosarcoma Cells by Up-regulating p21 via PAX3

Ryota Fujii  1 , Eiji Osaka  2 , Kentaro Sato  1 , Yasuaki Tokuhashi  1
Affiliations

MiR-1 Suppresses Proliferation of Osteosarcoma Cells by Up-regulating p21 via PAX3

Ryota Fujii et al. Cancer Genomics Proteomics. 2019 Jan-Feb.

Abstract

Background/aim: miRNA-1(miR-1) is down-regulated in various cancer cells including osteosarcoma cells. This study was conducted to analyze the function of miR-1 in osteosarcoma cells.

Materials and methods: miR-1 expression in osteosarcoma cells was evaluated by qRT-PCR. Cell proliferation was evaluated after transfecting miR-1 by WST8 assay and FACS analysis, both in vitro and in vivo.

Results: Overexpression of miR-1 suppressed cell proliferation and induced cell-cycle arrest in the G0-G1 phase by increasing p21 levels via a p53-independent pathway. Overexpression of miR-1 down-regulated PAX3, a potential p21-regulating gene. Moreover, knockdown of PAX3 suppressed cell proliferation by increasing p21 levels, and induced arrest at the G0/G1 phase. Administration of miR-1 showed an in vivo antitumor effect.

Conclusion: Overexpression of miR-1 suppressed cell proliferation and induced arrest in the G0/G1 phase by increasing p21 levels via a p53-independent pathway through PAX3 suppression. These results indicate that miR-1 could be a therapeutic target for osteosarcoma.

Keywords: Osteosarcoma; PAX3; miR-1; p21; p53-independent pathway.

PubMed Disclaimer

Conflict of interest statement

No potential conflicts of interest were reported by the Authors.

Figures

Figure 1
Figure 1. Expression level of miR-1. A: Expression levels of miR-1 in the osteosarcoma cell lines (MG63, Saos2, G292) and normal cell line (hFOB1.19). B: Changes in miR-1 expression levels 48 h after transfection of the osteosarcoma cell line MG63 with miR-1 (50 nM). *p<0.05.
Figure 2
Figure 2. Evaluation of cell proliferation and cell cycle after transfection of miR-1 and NC-miRNA in the osteosarcoma cell line. A: Cell proliferation at 24, 48, and 72 hs. B: Phase of cell cycle at 48 h. C: Analysis of p21 expression levels by qRT-PCR. D: Western blot analysis of the expression of p21, p53, phosphorylated p53, and p73 at 48 h by. *p<0.05, **p<0.01.
Figure 3
Figure 3. The effect of transfection of miR-1 or NC-miRNA in the osteosarcoma cell line (MG63) on PAX3 levels. A: The miR-1 sequence and target area in PAX3. B: qRT-PCR analysis of PAX3 expression at 48 h and C: western blot analysis of PAX3 expression at 48 h.
Figure 4
Figure 4. Evaluation of cell proliferation and cell cycle after transfection of siPAX3 and NC-siRNA (10 nM) in the osteosarcoma cell line. A: qRTPCR analyses of PAX3 expression at 48 h. B: Western blot analysis of PAX3 expression at 48 h. C: Cell proliferation at 24, 48, and 72 h. D: Distribution of cells in each phase of the cell cycle at 48 h. E: qRT-PCR analysis of p21 expression levels and F: western blot analysis of p21 expression levels. *p<0.05, **p<0.01.
Figure 5
Figure 5. The mouse subcutaneous tumor model was prepared, and miR-1 or NC-miRNA were administered around the tumor (each n=6). miRNA 3 times on Days 0, 7, and 14. A: Changes in tumor volume over time. B: Tumor appearance C: Ki67 staining of tumor tissues. D: Evaluation of proliferation activity by scoring. *p<0.05, **p<0.01.
See this image and copyright information in PMC

References

    1. Uribe-Botero G, Russell WO, Sutow WW, Martin RG. Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54. Am J Clin Pathol. 1977;67(5):427–435. - PubMed
    1. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H, Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20(3):776–790. - PubMed
    1. Kempf-Bielack B, Bielack SS, Jurgens H, Branscheid D, Berdel WE, Exner GU, Gobel U, Helmke K, Jundt G, Kabisch H, Kevric M, Klingebiel T, Kotz R, Maas R, Schwarz R, Semik M, Treuner J, Zoubek A, Winkler K. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS) J Clin Oncol. 2005;23(3):559–568. - PubMed
    1. Szuhai K, Cleton-Jansen AM, Hogendoorn PC, Bovee JV. Molecular pathology and its diagnostic use in bone tumors. Cancer Genet. 2012;205(5):193–204. - PubMed
    1. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014;9:287–314. - PMC - PubMed

MeSH terms